Binding molecules specific for ASCT2 and uses thereof
This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
MedImmune, LLC
C A A C C C G A A C A C A C A C C
C07K A61P A61K C07K C07K C07K G01N A61K A61K C07K A61K C07K A61K C07K A61K C07K C07K
additional inventional inventional additional additional inventional inventional additional inventional additional inventional additional inventional additional inventional additional additional
Partha Chien-Ying Robert E. Nabendu Martin J. David A. Emil F.
Chowdhury Chang Hollingsworth Pore Borrok, III Tice Michelotti